

Resource Summary Report

Generated by [NIF](#) on Sep 9, 2026

HCC827

RRID:CVCL_2063

Type: Cell Line

Proper Citation

RRID:CVCL_2063

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2063

Proper Citation: RRID:CVCL_2063

Description: Cell line HCC827 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Lung adenocarcinoma

Defining Citation: [PMID:9559342](#), [PMID:10987304](#), [PMID:11314036](#), [PMID:16187286](#), [PMID:18083107](#), [PMID:20215515](#), [PMID:20679594](#), [PMID:22460905](#), [PMID:22751098](#), [PMID:22961666](#), [PMID:23733853](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:25984343](#), [PMID:26361996](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:29681454](#), [PMID:30038707](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:32163227](#), [PMID:35117401](#), [PMID:35839778](#), [PMID:39061985](#)

Comments: Karyotypic information: Flat-moded hypotriploid karyotype with 6% polyploidy (DSMZ=ACC-566)., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: EGFR genetic alteration cell panel (ATCC TCP-1027)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC827

Synonyms: HCC-827, HCC 827, HCC0827, HCC827-P, Hamon Cancer Center 827

Cross References: BTO:BTO_0004082, CLO:CLO_0003659, CLO:CLO_0037015, EFO:EFO_0003137, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2868, BCRJ:0351, BioGRID_ORCS_Cell_line:424, BioSample:SAMN03472697, BioSample:SAMN10988440, cancercellines:CVCL_2063, CCRID:1101HUM-PUMC000478, CCRID:3101HUMSCSP538, CCRID:3101HUMTCHu153, Cell_Model_Passport:SIDM01067, ChEMBL-Cells:ChEMBL4295384, ChEMBL-Targets:ChEMBL4296422, CLS:305041, Cosmic:903634, Cosmic:1028936, Cosmic:1128251, Cosmic:1146941, Cosmic:1219071, Cosmic:1352407, Cosmic:1802300, Cosmic:1995436, Cosmic:2125263, Cosmic-CLP:1240146, DepMap:ACH-000012, DSMZ:ACC-566, DSMZCellDive:ACC-566, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1240146, GEO:GSM63350, GEO:GSM108883, GEO:GSM108884, GEO:GSM183436, GEO:GSM183437, GEO:GSM253425, GEO:GSM434274, GEO:GSM466319, GEO:GSM513969, GEO:GSM514323, GEO:GSM784276, GEO:GSM794382, GEO:GSM817117, GEO:GSM827206, GEO:GSM844553, GEO:GSM887060, GEO:GSM888130, GEO:GSM935083, GEO:GSM938752, GEO:GSM938753, GEO:GSM938754, GEO:GSM938755, GEO:GSM938756, GEO:GSM938757, GEO:GSM1557132, GEO:GSM1669864, Hysigen:TCH-C182, IARC_TP53:28333, IGRhCellID:HCC827GEO, KCLB:70827, LiGeA:CCLE_221, LINCS_LDP:LCL-1608, PharmacDB:HCC827_512_2019, PRIDE:PXD002556, PRIDE:PXD030304, Progenetix:CVCL_2063, PubChem_Cell_line:CVCL_2063, Ubigen:YC-C043, Wikidata:Q54881781

ID: CVCL_2063

Record Creation Time: 20220427T220319+0000

Record Last Update: 20260905T180221+0000

Ratings and Alerts

No rating or validation information has been found for HCC827.

No alerts have been found for HCC827.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 1324 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

van Tienen LM, et al. (2026) Systematic cysteine scanning identifies a druggable pocket in oncogenic KRAS. Cell chemical biology, 33(2), 241.

Zhang H, et al. (2026) Unveiling poliumoside: A herbal-derived FAK kinase inhibitor with anti-proliferative and anti-metastatic efficacy. *Phytomedicine : international journal of phytotherapy and phytopharmacology*, 150, 157747.

Zhang Z, et al. (2026) A Moderate-Affinity Antibody-Drug Conjugate Targeting B7-H3 Exerts Potent Antitumor Efficacy. *Pharmaceuticals (Basel, Switzerland)*, 19(4).

Chang TH, et al. (2026) The STAT3-ZEB1 axis contributes to CCL2-mediated resistance to osimertinib in lung cancer. *Frontiers in oncology*, 16, 1699471.

Zhang H, et al. (2026) Coordinated DNA 5-mC and RNA m5C methylation epigenetically regulates MZF1 splice variants to drive EGFR-TKI resistance. *Experimental & molecular medicine*, 58(7), 2138.

Gao Y, et al. (2026) AMT inhibits the progression of non-small cell lung cancer by suppressing the PI3K/AKT/GSK-3 β -catenin pathway via H3K27me3 regulation. *European journal of pharmacology*, 1011, 178460.

Zhu L, et al. (2026) Mitochondrial glutamine import sustains electron transport chain integrity independently of glutaminolysis in cancer. *Molecular cell*, 86(1), 150.

Li SY, et al. (2026) ABTB1 modulates EGFR signaling and confers icotinib sensitivity in lung adenocarcinoma. *Respiratory research*, 27(1).

Li Y, et al. (2026) Mitigating tumor heterogeneity in lung Cancer: A dual-targeted NIR-II imaging strategy for accurate tumor localization and intraoperative navigation. *Cancer letters*, 640, 218241.

Nilsson MB, et al. (2026) Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*, 21(6), 103555.

Cáceres-Verschae A, et al. (2026) Profiling of Extracellular Vesicles of Non-Small Cell Lung Cancer Reveals Proteins Associated With Osimertinib Resistance. *Journal of extracellular vesicles*, 15(1), e70219.

Chen Y, et al. (2026) PFKFB4 Deubiquitination by USP10 Enhances Fumarate Metabolism to Orchestrate the KDM1A/Rad51 Axis and Confer Radioresistance in Lung Cancer. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e76439.

Li J, et al. (2026) Lactylation Enhances the Activity of Lactate Dehydrogenase A and Promotes the Chemoresistance to Cisplatin Through Facilitating DNA Nonhomologous End Junction in Lung Adenocarcinoma. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(3), e10733.

Liu T, et al. (2026) Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer. *Cancer research*, 86(5), 1215.

Pan K, et al. (2026) Lysine methylation-mediated SMYD2 degradation by casticin sensitizes non-small-cell lung cancer cells to osimertinib therapy. *Biochemical*

pharmacology, 243(Pt 2), 117562.

Lee CH, et al. (2026) Dynamic 3D imaging system detects vasculogenic mimicry and screens inhibitors in EGFR-mutant lung cancer. *Translational research : the journal of laboratory and clinical medicine*, 296, 122.

Takano K, et al. (2026) DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. *Molecular cancer therapeutics*, 25(1), 7.

Stern YE, et al. (2026) Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors. *Cancer research*, 86(2), 485.

Lee EJ, et al. (2026) JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(9), 1835.

Zhao W, et al. (2026) C1RL-AS1/microRNA-424-5p/adrenoceptor $\beta 2$ axis: A novel regulatory mechanism in lung adenocarcinoma associated with immune infiltration and prognosis. *PloS one*, 21(3), e0343805.